CTV: Study shows gender bias in physician referrals
UC expert says findings reveal lingering implicit bias affecting women surgeons
Gender bias persists when it comes to physicians referring patients to surgeons, according to a new Canadian study.
The study found that male surgeons in Ontario made up 77.5% of all surgeons but received 79% of referrals from female physicians and 87% of referrals from male physicians from 1997-2016.
Elizabeth Shaughnessy, MD, PhD, professor and vice chair of patient experience in the University of Cincinnati's Department of Surgery in the College of Medicine, a UC Health breast cancer surgeon and president of the Association of Women Surgeons, said the study shows less obvious forms of gender discrimination continue in medical settings.
"We're seeing it in its more subtle forms which is far more difficult to identify and eradicate, which is disturbing to us because as women surgeons, we certainly suspect that this has been going on for a while and this just helps to confirm certain suspicions," Shaughnessy told CTV News Canada.
Featured photo at top of Dr. Shaughnessy and colleagues in surgery. Photo/Colleen Kelley/University of Cincinnati
Related Stories
Machine learning aids in detection of 'brain tsunamis'
March 21, 2025
MSN highlighted research led by the University of Cincinnati's Jed Hartings detailing how automation and machine learning can aid clinicians treating patients with spreading depolarizations, sometimes referred to as “brain tsunamis.”
Ancient Greek jar holds curse against 55 people
March 20, 2025
The Greek Reporter talks about the 2006 discovery of a curse jar by a UC Classics student during an excavation of an Athens marketplace.
Combination therapy is not beneficial for certain patients with...
March 20, 2025
OncLive and MedPage Today highlighted research presented by the University of Cincinnati Cancer Center's Thomas Herzog that found a combination therapy of afuresertib and paclitaxel did not lead to better survival outcomes when compared to only treating with paclitaxel in patients with platinum-resistant ovarian cancer.